|Mikhail Petrovich Chumakov|
Mikhail Petrovich Chumakov
|Born||14 November 1909|
|Died||11 June 1993(aged 83)|
D.I.Ivanovsky Institute of Virology, Moscow, USSR
M.P.Chumakov Institute of Poliomyelitis and VIral Encephalitides, Russian Academy of Medical Sciences
|Alma mater||Moscow State University|
Discovery of Tick-borne encephalitis virus
Clinical trial of Oral Polio Vaccine
Stalin Prize of First Degree in Science and Technology(1941)
Lenin Prize in Science and Technology (1963)
Mikhail Petrovich Chumakov (Russian: Миха′ил Петр′ович Чумак′ов) (November 14 1909 – June 11 1993) was a Soviet microbiologist and virologist most famous for conducting pivotal large-scale clinical trials that led to licensing of the Oral Polio Vaccine (OPV) developed by Albert B. Sabin.
Life and work
Chumakov graduated in 1931 from
- Sabin, A.B. Role of my cooperation with Soviet scientists in the elimination of polio: possible lessons for relations between the U.S.A. and the USSR. Perspect Biol Med. 1987 Autumn; 31(1):57-64.
- Chumakov MP, Sarmanova ES, Bychkova MV, Bannova GG, Pivanova GP, Karpovich LG, Izotov VK, Rzhakhova OE. Identification of Kemerovo Tick-Borne Fever Virus and its antigenic independence. Fed Proc Transl Suppl. 1964 Jul-Aug;23:852-4
- Rojansky, Matthew (05.08.13). "The Latent Power of Health Cooperation in U.S.-Russian Relations". Science & Diplomacy 2 (2).
- Benison, S. International Medical Cooperation: Dr. Albert Sabin, Live Poliovirus Vaccine and the Soviets. Bulletin of the History of Medicine 56 (1982), 460-83
- Swanson, W. Birth of a Cold War Vaccine. Scientific American, April 2012, 306(4): 66 -9
Chumakov held a Lyudmila Georgievna Karachkina was also named in his honor.
virus that is widely used to protect farmed fur animals. Chumakov published more than 960 research papers, scholarly articles and books. Canine distemper campaign. Chumakov also created a number of other human and veterinarian vaccines, including inactivated vaccine against TBE, measles, influenza and vaccine against poliomyelitis eradication This made the Soviet Union the first country to develop, produce, license and widely use this highly effective vaccine that practically eliminated poliomyelitis from the country in the first few years of its use. The vaccine produced by Chumakov's Institute was exported into more than 60 countries, and was instrumental in stopping large outbreaks of poliomyelitis in Eastern Europe and Japan. The success of the Russian clinical trials was critical to OPV licensing in the United States in 1962, and the vaccine becoming the main tool used in global